Skip to content
OVistoaIntelligence index
AboutMethodologyPricingDocs
Sign inSign up
BREAKINGPerson found dead in car after it plows into health club in Portland, Oregon2 hr ago
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthSportsAviationArtificial IntelligencePublishers

Five-way obesity drug is super effective — in mice

1 articles · 1 outlets · spread 0.00

Five-way obesity drug is super effective — in mice
biotech3 d ago

Five-way obesity drug is super effective — in mice

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.008 claims
OVistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

0 outlets

No coverage from this perspective yet.

From the Center

1 outlet
  • STAT·Apr 30

    Five-way obesity drug is super effective — in mice

    Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Move over, GLP-1s. A preclinical next-gen obesity drug is stacking five mechanisms (in mice). Also, the NIH funding climate is rougher than ever, Novartis is reshoring more of its manufacturing, and another Alzheimer’s program is scuttled. The need-to-know this morning More pharma earnings: Merck, Bristol Myers Squibb and Eli Lilly Notable biotech earnings: Alnylam. UniQure said it will submit a marketing application for its Huntington’s disease gene therapy to U.K. regulators in the third quarter. Craig Venter, scientist, genomic pioneer and entrepreneur, died. It’s far harder to get an NIH grant these days The odds of landing an NIH grant have cratered to near-unsustainable levels. Only 13% of applications were funded last year, STAT’s Anil Oza writes, with even top-scoring proposals no longer having good odds. Now, researchers are scrambling to survive in a system that’s become both hypercompetitive and opaque. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

STAT

First seen

Apr 30, 2026

Latest

Apr 30, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.